Jun 2026 (Q2 FY26) — Aug 10, 2026
Hims & Hers Health Q2 FY26 — Strong Subscriber Growth and Strategic AI Investments
Read the full callHims & Hers Health (HIMS) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Hims & Hers Health earnings: last reported Mon, 10 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 753 | +38.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -12.9 | −17.8 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -86.3 | −303.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$28.15 +0.29% · +$0.08
Performance −43.5% 1Y
1Y: $49.78 on 17 Oct 2025 → $28.15. High $51.36 (20 Oct 2025), low $14.52 (27 Feb 2026).
- Previous close
- $28.07
- 52-week range
- $14.52 – $51.36
- One year
- −45.19%
Overview
- Symbol
- HIMS
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Mar 2026 (Q1 FY26) — May 11, 2026
Hims & Hers Q1 FY26 — Strategic Pivot Drives Accelerated Growth and Long-Term Confidence
Read the full callDec 2025 (Q4 FY25) — Feb 23, 2026
Hims & Hers Q4 FY25 — Strong Growth, International Expansion, and Strategic Investments
Read the full callEvery analysed call
Hims & Hers Health earnings calls (HIMS)
Financials
What the filings say
Net profit, year on year: −303% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 402 | 481 | 586 | 545 | 599 | 618 | 608 | 753 |
| Operating profit | 22 | 19 | 58 | 27 | 12 | 9 | -78 | -97 |
| Operating margin | 5.6% | 3.9% | 9.9% | 4.9% | 2.0% | 1.5% | −12.9% | −12.9% |
| Other income | 1 | 4 | 3 | 6 | 0 | 9 | -23 | 5 |
| Profit before tax | 24 | 22 | 60 | 33 | 12 | 18 | -102 | -93 |
| Tax rate | −220.4% | −16.8% | 18.2% | −29.4% | −29.1% | −12.3% | 9.3% | 6.8% |
| Net profit | 76 | 26 | 49 | 43 | 16 | 21 | -92 | -86 |
| EPS ($ per share) | 0.35 | — | 0.22 | 0.19 | 0.07 | — | -0.40 | -0.37 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Equity capital | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | 1 | -171 | -279 | -345 | -368 | -242 | -114 |
| Total liabilities | 8 | 16 | 86 | 55 | 97 | 231 | 1,614 |
| Fixed assets | — | 2 | 2 | 3 | — | — | — |
| Total assets | 205 | 119 | 421 | 366 | 441 | 708 | 2,155 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -75 | -2 | -34 | -27 | 73 | 251 | 300 |
| Cash from investing | -39 | -40 | -156 | 35 | -12 | -19 | -1,025 |
| Cash from financing | 95 | 48 | 235 | -33 | -11 | -108 | 730 |
| Net cash flow | -19 | 6 | 44 | -25 | 50 | 124 | 7 |
| Capital expenditure | — | — | — | -7 | -26 | -53 | -243 |
| Free cash flow | — | — | — | -34 | 47 | 198 | 57 |
HIMS revenue by segment
| Segment | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|
| Single Reporting | 100% | — |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
HIMS operating KPIs by quarter
| KPI | Dec 2025 Q4 FY25 | Mar 2026 Q1 FY26 | Change vs prior quarter |
|---|---|---|---|
| Subscribers | 2.5M+At the end of 2025, over 2.5 million subscribers on our platform were benefiting from our pursuit of this vision.Source: earnings call transcript | <2.6MIn the first quarter, revenue grew 4% year-over-year to $608 million, subscribers grew 9% year-over-year to nearly 2.6 million and adjusted EBITDA was $44 million, representing a 7% adjusted EBITDA margin.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Revenue by region
Q2 FY2026 · share of revenue
- US 83% ↓ 5 pt
- Non Us 17% ↑ 5 pt
As HIMS cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
166 filings between Oct 27, 2025 and Oct 14, 2026.
Open market
decisions to buy or sellPurchases
$1.17M
1 purchase by 1 insider
Sales
$19.42M
46 sales by 8 insiders
98% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 4
- Award — granted as compensation
- 68
- Option exercise — converted options into shares
- 33
- Tax withheld — shares kept back by the company to cover tax
Also filed: 12 gifts, 2 other filings.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Okupe Oluyemi | — | $9.69M | Oct 1, 2026 |
| Chi Michael | — | $3.75M | Sep 15, 2026 |
| Boughton Soleil | — | $1.98M | Oct 14, 2026 |
| Carroll Patrick Harrison | — | $1.20M | Jun 18, 2026 |
| WELLS DAVID B | $1.17M | — | May 26, 2026 |
| Elshenawy Mohamed | — | $1.17M | Sep 15, 2026 |
| Becklund Irene | — | $815.8K | Jun 17, 2026 |
| Autor Deborah M. | — | $726.1K | Aug 18, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 14, 2026 | Boughton Soleil Chief Legal Officer | Sale 10b5-1 plan | 3,461 | $100.6K |
| Oct 1, 2026 | Okupe Oluyemi Chief Financial Officer | Sale 10b5-1 plan | 2,000 | $59.4K |
| Sep 30, 2026 | Boughton Soleil Chief Legal Officer | Sale 10b5-1 plan | 3,461 | $101.0K |
| Sep 22, 2026 | Okupe Oluyemi Chief Financial Officer | Option exercise 10b5-1 plan | 14,000 | $70.1K |
| Sep 22, 2026 | Okupe Oluyemi Chief Financial Officer | Sale 10b5-1 plan | 29,277 | $876.8K |
| Sep 17, 2026 | Okupe Oluyemi Chief Financial Officer | Sale 10b5-1 plan | 12,313 | $354.9K |
| Sep 16, 2026 | Boughton Soleil Chief Legal Officer | Sale 10b5-1 plan | 6,236 | $173.7K |
| Sep 15, 2026 | Chi Michael Chief Operating Officer | Sale 10b5-1 plan | 14,027 | $398.2K |
| Sep 15, 2026 | Elshenawy Mohamed CTO | Sale 10b5-1 plan | 7,954 | $225.8K |
| Sep 2, 2026 | Boughton Soleil Chief Legal Officer | Sale 10b5-1 plan | 3,458 | $98.0K |
| Aug 27, 2026 | Dudum Andrew Chief Executive Officer | Other | 977,566 | $0 |
| Aug 25, 2026 | Dudum Andrew Chief Executive Officer | Gift | 463,289 | $0 |
| Aug 19, 2026 | Okupe Oluyemi Chief Financial Officer | Option exercise 10b5-1 plan | 4,938 | $24.7K |
| Aug 19, 2026 | Boughton Soleil Chief Legal Officer | Sale 10b5-1 plan | 25,111 | $691.8K |
| Aug 19, 2026 | Okupe Oluyemi Chief Financial Officer | Sale 10b5-1 plan | 4,938 | $148.1K |
| Aug 18, 2026 | Autor Deborah M. Chief Policy Officer | Sale 10b5-1 plan | 16,773 | $467.1K |
| Aug 17, 2026 | Okupe Oluyemi Chief Financial Officer | Sale 10b5-1 plan | 9,388 | $261.8K |
| Aug 17, 2026 | Okupe Oluyemi Chief Financial Officer | Option exercise 10b5-1 plan | 9,388 | $47.0K |
| Aug 14, 2026 | Okupe Oluyemi Chief Financial Officer | Tax withheld 10b5-1 plan | 36,437 | $1.03M |
| Aug 14, 2026 | Okupe Oluyemi Chief Financial Officer | Option exercise 10b5-1 plan | 71,616 | — |
| Aug 14, 2026 | Payne Christopher D Director | Option exercise | 545 | — |
| Aug 14, 2026 | Autor Deborah M. Chief Policy Officer | Tax withheld | 16,147 | $454.5K |
| Aug 14, 2026 | Schultz Kare Director | Option exercise | 6,623 | — |
| Aug 14, 2026 | Carroll Patrick Harrison Chief Medical Officer | Tax withheld | 10,201 | $287.2K |
| Aug 14, 2026 | Boughton Soleil Chief Legal Officer | Option exercise | 42,261 | — |
| Aug 14, 2026 | Boughton Soleil Chief Legal Officer | Tax withheld | 21,500 | $605.2K |
| Aug 14, 2026 | Becklund Irene PAO | Option exercise | 13,685 | — |
| Aug 14, 2026 | Becklund Irene PAO | Tax withheld | 6,490 | $182.7K |
| Aug 14, 2026 | Carroll Patrick Harrison Chief Medical Officer | Option exercise | 25,927 | — |
| Aug 14, 2026 | Autor Deborah M. Chief Policy Officer | Option exercise | 32,920 | — |
| Aug 14, 2026 | Carroll Patrick Harrison Chief Medical Officer | Option exercise | 260 | — |
| Aug 14, 2026 | Dudum Andrew Chief Executive Officer | Tax withheld | 78,859 | $2.22M |
| Aug 14, 2026 | Dudum Andrew Chief Executive Officer | Option exercise | 154,993 | — |
| Aug 14, 2026 | WELLS DAVID B Director | Option exercise | 778 | — |
| Aug 14, 2026 | Chi Michael Chief Operating Officer | Tax withheld | 47,702 | $1.34M |
| Aug 14, 2026 | Chi Michael Chief Operating Officer | Option exercise | 86,265 | — |
| Aug 14, 2026 | Elshenawy Mohamed CTO | Option exercise | 188,285 | — |
| Aug 14, 2026 | Elshenawy Mohamed CTO | Tax withheld | 95,798 | $2.70M |
| Jul 17, 2026 | Okupe Oluyemi Chief Financial Officer | Sale 10b5-1 plan | 7,163 | $229.2K |
| Jul 17, 2026 | Okupe Oluyemi Chief Financial Officer | Option exercise 10b5-1 plan | 7,163 | $35.9K |
| Jul 6, 2026 | Okupe Oluyemi Chief Financial Officer | Sale 10b5-1 plan | 7,163 | $261.4K |
| Jul 6, 2026 | Okupe Oluyemi Chief Financial Officer | Option exercise 10b5-1 plan | 7,163 | $35.9K |
| Jun 22, 2026 | Okupe Oluyemi Chief Financial Officer | Sale 10b5-1 plan | 18,197 | $619.2K |
| Jun 22, 2026 | Okupe Oluyemi Chief Financial Officer | Option exercise 10b5-1 plan | 6,376 | $31.9K |
| Jun 18, 2026 | Okupe Oluyemi Chief Financial Officer | Sale 10b5-1 plan | 55,383 | $1.94M |
| Jun 18, 2026 | Carroll Patrick Harrison Chief Medical Officer | Sale 10b5-1 plan | 23,726 | $830.4K |
| Jun 17, 2026 | Elshenawy Mohamed CTO | Sale 10b5-1 plan | 30,040 | $946.3K |
| Jun 17, 2026 | Becklund Irene PAO | Sale 10b5-1 plan | 4,490 | $141.4K |
| Jun 17, 2026 | Chi Michael Chief Operating Officer | Sale 10b5-1 plan | 14,027 | $441.9K |
| Jun 16, 2026 | Becklund Irene PAO | Sale 10b5-1 plan | 7,573 | $229.1K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Hims & Hers Health, Inc.
Free account. Everything above stays public.
Write why you follow Hims & Hers Health, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading